Illumina and Amgen-backed genomic sequencing technology developer Oxford Nanopore has added $59.6m to a round that now totals $98.1m.
Oxford Nanopore, a UK-based genetic sequencing technology that counts pharmaceutical firm Amgen and genomics technology provider Illumina as investors, expanded its latest funding round to $98.1m today.
The company secured £48.4m ($59.6m) from undisclosed new and existing investors, adding to a $38.5m first tranche in January this year. Although it has not disclosed the identity of the round’s participants, they included investors from the US, Middle East, Europe, Africa and the Asia-Pacific region.
Existing investors in Oxford Nanopore had…
